Skip to main content

Table 1 Subject characteristics

From: Clinical and multimodal biomarker correlates of ADNI neuropathological findings

  AD AD + MTL pathology AD + DLB AD + DLB + MTL pathology p-value
  n = (7) n = (5) n = (6) n = (4)
Longitudinal clinical diagnosis 1 CN to MCI 1 MCI stable 1 MCI to DAT 2 MCI to DAT -
2 MCI stable 3 MCI to DAT
1 DAT 5 DAT
2 DAT
2 MCI to DAT
2 DAT
Neuropathological diagnosis 1 LNC AD 1HNC AD + MTL-TDP 1 HNC AD + DLB 1 DLB-LNC -
3 HNC AD AD + AGD
3 HNC AD + SVD-I 2 LNC AD + AGD + MTL-TDP 3 HNC 1 DLB- LNC AD + MTL-TDP
2 HNC AD + DLB + MTL-TDP
1HNC AD + AGD + MTL-TDP + HS
1HNC AD + AGD + MTL-TDP + HS + SVD-I
  AD- + DLB
  1 HNC AD-DLB + SVD-I
  1 DLB + LNC AD
Age at death (years) 2 80 (77–83) 86 (82–88) 80.5 (72.25-83.75) 81 (77.75-84.75) 0.41
Gender (n male/total) 3/7 4/5 6/6 4/4 1.0
Education (years) 1 15.4 (2.4) 15.0 (2.4) 16.1 (2.6) 14.0 (2.3) 0.62
Baseline visit to death (weeks) 2 240.7 (98.7-256.8) 181.9 (108.4-289.0) 136.5 (80.9-278.3) 234.9 (189.1-257.1) 0.72
APOE ϵ4 (n positive/total) 4/7 1/5 5/6 1/3 0.18
ADAS-Cog (13 item) baseline 2 20.0 (10.3-28.0) 22.0 (17.7-29.0) 33.3 (18.0-54.7) 30.3 (25.3-35.0) 0.041
1-42 (pg/mL) 2 134.0 (86.0-261.0) 249.0 (123.0-261.0) 138.0 (82.0-152.0) 171.0 (134.0-201.9) 0.59
T-Tau (pg/mL) 2 141.5 (60.0-274.0) 65.0 (55.0-89.0) 88.0 (37.0-154.0) 73.0 (56.0-103.6) 0.61
P-Tau181 (pg/mL) 2 51.0 (17.0-70.0) 22.0 (12.0-33.0) 28.0 (11.0-45.0) 21.0 (19.0-24.0) 0.32
  1. 1Mean (Standard Deviation); 2Median (Minimum-Maximum).
  2. AGD: Argyrophilic grain disease; SVD-I: Small vessel disease (arteriolosclerosis and/or cerebral amyloid angiopathy) and one or more infarcts); HNC AD: High neuropathologic change Alzheimer’s disease; HS: Hippocampal sclerosis; LNC AD: Low neuropathological change Alzheimer’s disease; MTL-TDP: TDP pathology circumscribed to the medial temporal lobe.